Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1191990916 | 11919909 | 16 | F | 20151212 | 20160630 | 20160115 | 20160705 | EXP | CN-009507513-1512CHN014118 | MERCK | 57.00 | YR | M | Y | 63.00000 | KG | 20160705 | MD | CN | CN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1191990916 | 11919909 | 1 | PS | EMEND | APREPITANT | 1 | Oral | 125 MG, ONCE ON DAY 1 | Y1250 | 21549 | 125 | MG | CAPSULE | 1X | |||||
| 1191990916 | 11919909 | 2 | SS | EMEND | APREPITANT | 1 | Oral | 80 MG, ON DAY 2 | Y1250 | 21549 | 80 | MG | CAPSULE | 1X | |||||
| 1191990916 | 11919909 | 3 | SS | EMEND | APREPITANT | 1 | Oral | 80 MG, ON DAY 3 | Y1250 | 21549 | 80 | MG | CAPSULE | 1X | |||||
| 1191990916 | 11919909 | 4 | C | CISPLATIN. | CISPLATIN | 1 | Intravenous drip | 40 MG, D1 TO D3, CYCLE:2/UNK | 25.4029999 | MG | U | 0 | 40 | MG | INJECTION | ||||
| 1191990916 | 11919909 | 5 | C | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Intravenous drip | 1.6 G, D1 AND D8; TREATMENT CYCLE 2/UNK | U | 0 | 1.6 | G | INJECTION | ||||||
| 1191990916 | 11919909 | 6 | C | CARBAZOCHROME SODIUM SULFONATE | CARBAZOCHROME SODIUM SULFONATE | 1 | Intravenous drip | 80 MG, QD | 800 | MG | U | 0 | 80 | MG | INJECTION | QD | |||
| 1191990916 | 11919909 | 7 | C | BISACODYL. | BISACODYL | 1 | Oral | 5 MG, QPM (QN) | 30 | MG | U | 0 | 5 | MG | TABLET | QD | |||
| 1191990916 | 11919909 | 8 | C | codeine phosphate (+) ibuprofen | 2 | Oral | TOTAL DAILY DOSE 0.426 G, BID | U | 0 | SUSTAINED RELEASE TABLET | BID | ||||||||
| 1191990916 | 11919909 | 9 | C | TROPISETRON HYDROCHLORIDE | TROPISETRON HYDROCHLORIDE | 1 | Intravenous drip | 5 MG, QD | 16.6040001 | MG | U | 0 | 5 | MG | INJECTION | QD | |||
| 1191990916 | 11919909 | 10 | C | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | Intravenous drip | 30 MG, QD | 100.834 | MG | U | 0 | 30 | MG | INJECTION | QD | |||
| 1191990916 | 11919909 | 11 | C | PHOSPHATIDYL CHOLINE | LECITHIN | 1 | Intravenous drip | 20 MG, QD | U | 0 | 20 | MG | INJECTION | QD | |||||
| 1191990916 | 11919909 | 12 | C | PYRIDOXINE | PYRIDOXINE | 1 | Intravenous drip | 200 MG, QD | 400 | MG | U | 0 | 200 | MG | INJECTION | QD | |||
| 1191990916 | 11919909 | 13 | C | DOXOFYLLINE | DOXOFYLLINE | 1 | Intravenous drip | 0.2 G, QD | U | 0 | .2 | G | INJECTION | QD | |||||
| 1191990916 | 11919909 | 14 | C | BROMHEXINE HYDROCHLORIDE | BROMHEXINE HYDROCHLORIDE | 1 | Intravenous drip | 4 MG, QD | 36 | MG | U | 0 | 4 | MG | INJECTION | QD | |||
| 1191990916 | 11919909 | 15 | C | JAVA BRUCEA | 2 | Intravenous drip | 30 ML/CC, QD, FORMULATION OIL EMULSION | 270 | ML | U | 0 | 30 | ML | INJECTION | QD | ||||
| 1191990916 | 11919909 | 16 | C | THYMALFASIN | THYMALFASIN | 1 | Subcutaneous | TOTAL DAILY DOSE 1.6 MG, BIW | U | 0 | INJECTION | BIW | |||||||
| 1191990916 | 11919909 | 17 | C | XUAN FEI ZHI KE HEI JI | 2 | Oral | TOTAL DAILY DOSE 20 ML/CC, TID | U | 0 | ORAL LIQUID | TID | ||||||||
| 1191990916 | 11919909 | 18 | C | CEPHRADINE | CEPHRADINE | 1 | Intravenous drip | TOTAL DAILY DOSE: 2G, BID | U | 0 | INJECTION | BID | |||||||
| 1191990916 | 11919909 | 19 | C | PROMETHAZINE | PROMETHAZINEPROMETHAZINE HYDROCHLORIDE | 1 | Intramuscular | 25 MG, QD | 50 | MG | U | 0 | 25 | MG | INJECTION | QD | |||
| 1191990916 | 11919909 | 20 | C | DEXAMETHASONE. | DEXAMETHASONE | 1 | Intravenous (not otherwise specified) | 5 MG, QD | 16.5990009 | MG | U | 0 | 5 | MG | INJECTION | QD | |||
| 1191990916 | 11919909 | 21 | C | HEMOCOAGULASE | 2 | Subcutaneous | STRENGTH: 2 U, 2 UNITS DAILY | 20 | DF | U | 0 | 2 | DF | INJECTION | QD | ||||
| 1191990916 | 11919909 | 22 | C | DEXAMETHASONE SODIUM PHOSPHATE. | DEXAMETHASONE SODIUM PHOSPHATE | 1 | Intravenous (not otherwise specified) | 5 MG, ONCE | 5 | MG | U | 0 | 5 | MG | INJECTION | 1X | |||
| 1191990916 | 11919909 | 23 | C | IOVERSOL | IOVERSOL | 1 | Intravenous (not otherwise specified) | 67.8 G, ONCE | 67.8000031 | G | U | 0 | 67.8 | G | INJECTION | 1X |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 1191990916 | 11919909 | 1 | Prophylaxis of nausea and vomiting |
| 1191990916 | 11919909 | 4 | Chemotherapy |
| 1191990916 | 11919909 | 5 | Chemotherapy |
| 1191990916 | 11919909 | 6 | Haemorrhage prophylaxis |
| 1191990916 | 11919909 | 7 | Purging |
| 1191990916 | 11919909 | 8 | Cough |
| 1191990916 | 11919909 | 9 | Prophylaxis of nausea and vomiting |
| 1191990916 | 11919909 | 10 | Antacid therapy |
| 1191990916 | 11919909 | 11 | Liver disorder |
| 1191990916 | 11919909 | 12 | Prophylaxis of nausea and vomiting |
| 1191990916 | 11919909 | 13 | Wheezing |
| 1191990916 | 11919909 | 14 | Productive cough |
| 1191990916 | 11919909 | 15 | Neoplasm |
| 1191990916 | 11919909 | 16 | Immune enhancement therapy |
| 1191990916 | 11919909 | 17 | Productive cough |
| 1191990916 | 11919909 | 18 | Anti-infective therapy |
| 1191990916 | 11919909 | 19 | Vomiting |
| 1191990916 | 11919909 | 20 | Prophylaxis of nausea and vomiting |
| 1191990916 | 11919909 | 21 | Anticoagulant therapy |
| 1191990916 | 11919909 | 22 | Immune tolerance induction |
| 1191990916 | 11919909 | 23 | X-ray |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 1191990916 | 11919909 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 1191990916 | 11919909 | Anaemia | |
| 1191990916 | 11919909 | Asthenia | |
| 1191990916 | 11919909 | Constipation | |
| 1191990916 | 11919909 | Decreased appetite | |
| 1191990916 | 11919909 | Hepatic function abnormal | |
| 1191990916 | 11919909 | Neutrophil count decreased | |
| 1191990916 | 11919909 | Platelet count decreased | |
| 1191990916 | 11919909 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 1191990916 | 11919909 | 1 | 20151211 | 20151211 | 0 | |
| 1191990916 | 11919909 | 2 | 20151212 | 20151212 | 0 | |
| 1191990916 | 11919909 | 3 | 20151213 | 20151213 | 0 | |
| 1191990916 | 11919909 | 4 | 20151211 | 20151213 | 0 | |
| 1191990916 | 11919909 | 5 | 20151211 | 20151220 | 0 | |
| 1191990916 | 11919909 | 6 | 20151206 | 20151221 | 0 | |
| 1191990916 | 11919909 | 7 | 20151210 | 20151217 | 0 | |
| 1191990916 | 11919909 | 8 | 20151210 | 20151221 | 0 | |
| 1191990916 | 11919909 | 9 | 20151211 | 20151220 | 0 | |
| 1191990916 | 11919909 | 10 | 20151211 | 20151221 | 0 | |
| 1191990916 | 11919909 | 11 | 20151211 | 0 | ||
| 1191990916 | 11919909 | 12 | 20151211 | 20151213 | 0 | |
| 1191990916 | 11919909 | 13 | 20151202 | 20151210 | 0 | |
| 1191990916 | 11919909 | 14 | 20151202 | 20151210 | 0 | |
| 1191990916 | 11919909 | 15 | 20151202 | 20151210 | 0 | |
| 1191990916 | 11919909 | 16 | 20151202 | 20151221 | 0 | |
| 1191990916 | 11919909 | 17 | 20151202 | 20151210 | 0 | |
| 1191990916 | 11919909 | 18 | 20151204 | 20151210 | 0 | |
| 1191990916 | 11919909 | 19 | 20151211 | 20151213 | 0 | |
| 1191990916 | 11919909 | 20 | 20151211 | 20151220 | 0 | |
| 1191990916 | 11919909 | 21 | 20151206 | 20151221 | 0 | |
| 1191990916 | 11919909 | 22 | 20151202 | 20151202 | 0 | |
| 1191990916 | 11919909 | 23 | 20151202 | 20151202 | 0 |